|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 25, 2016 ) After entering China, atorvastatin develops fast with annual sales value rising from less than CNY 70 million in 2005 to CNY 1.374 billion in 2014 and CAGR reaching up to 41% during 2005-2014. Atorvastatin enjoys a vast demand in China. And such companies as Pfizer Inc (Ireland), Pfizer Inc (the US), Topfond and Beijing Jialin Pharmaceutical Co., Ltd occupy the market, among which Pfizer (the US) has the largest market share of about 65% in 2014 with sales value reaching up to CNY 895 million.
As the number of hyperlipidemia patients keeps growing, the sales value of atorvastatin is expected to increase in the next few years.
Request sample at : https://marketreportscenter.com/request-sample/133382
Readers can get at least the following information from this report:
-sales status of atorvastatin in China
-price of atorvastatin in Chinese market
-major manufacturers of atorvastatin in Chinese market
-share of dosage forms of atorvastatin in China
-market outlook of atorvastatin in China
Check for Discount at : https://marketreportscenter.com/request-discount/133382
The author suggests the following groups of people purchase this report:
-manufacturers of cardiovascular drugs
-investors/ research institutions interested in China cardiovascular drug market
-any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse full report with TOC : https://marketreportscenter.com/reports/133382/investigation-report-on-china-atorvastatin-market-2010-2019
Connect for more details:
Sam Collins
Market Reports Center
Call us : 1-646-883-3044 (US)
Email : info@marketreportscenter.com
visit our website : https://marketreportscenter.com
Market Reports Center
Sam Collins
1-646-883-3044
sam@marketreportscenter.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
